Drug Development Services for NAFLD

Ace Therapeutics aims to provide the most professional and comprehensive drug development services to NAFLD research clients worldwide.

NAFLD is one of the most common liver diseases worldwide, and there are no specific drugs for NAFLD. We offer comprehensive drug development services based on the specific pathology of NAFLD. We have a well-established and professional drug discovery platform and provide specialized research services to facilitate the progress of NAFLD drug discovery.

Fig.1 Pathogenic pathways involved in NAFLD. (Nassir, F. 2022)

What Can We Do?

There are no specific drugs for NAFLD and most of the drugs used to treat NAFLD are directed toward lipotoxicity, oxidative stress, mitochondrial dysfunction, fibrosis, and some other directions. Therefore, in addition to concentrating on the development of specific drugs for NAFLD, we offer exclusive research services for different areas.

• We provide drug screening platforms for pathways and targets related to NAFLD pathological processes to enable large-scale screening of drug candidates.
• We provide different in vitro and in vivo models of NAFLD to validate drug candidates.
• We provide a comprehensive preclinical drug evaluation platform to assess the therapeutic effects of drug candidates.

• NAFLD Drug Development for Lipotoxicity

Hepatocellular injury in NAFLD is characterized by endoplasmic reticulum stress, dysfunctional unfolded protein responses, and other pathological phenomena that concurrently lead to the development of lipotoxicity. We offer comprehensive research services in the field of developing drugs for lipotoxicity in NAFLD in order to solve your research challenges.

Our experts have extensive experience in the areas of endoplasmic reticulum stress, oxidative stress, and autophagy, which are commonly seen in the pathology of NAFLD, and are able to address the challenges of drug development projects with sensitivity and accuracy.

• NAFLD Drug Development for Mitochondrial Dysfunction

Given that mitochondrial dysfunction, an important target in NAFLD, promotes liver damage and accelerates disease progression through increased production of reactive oxygen species (ROS), oxidative stress, and bioenergetic defects, we offer comprehensive drug development services for mitochondrial dysfunction.

• To address the impact of mitochondrial ROS-producing function on NAFLD, we will conduct a large-scale screen for ROS-specific antioxidants to identify NAFLD-specific drugs.
• To address the impact of mitochondrial autophagy on NAFLD, we will target the PTEN-induced putative kinase 1 (PINK1)/Parkin pathway and other autophagy-related pathways in a targeted screen for drugs specific to NAFLD.

Ace Therapeutics has extensive research experience in the field of NAFLD. Our drug development services have been validated by multiple parties and can be customized exclusively to your research project. If you would like to learn more about our services, please feel free to contact us.

Reference

1. Nassir, F. Nafld: Mechanisms, treatments, and biomarkers. Biomolecules. 2022. 12(6).

Our products and services are for research use only and can not be used for diagnostic or other purposes.